PainChek Ltd (AU:PCK)
ASX:PCK
Top Page
PainChek Ltd
(Sydney:PCK)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.14
▼(-53.45% Downside)
Action:ReiteratedDate:03/31/26
The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and negative equity—despite improving revenue growth and gross margin and a debt-free balance sheet. Technicals remain broadly weak (below longer-term averages with negative MACD), and valuation lacks support given negative earnings and no dividend.
Positive Factors
Recurring SaaS model in aged/dementia care
PainChek’s core SaaS licensing to aged‑care and clinical providers creates recurring, contractable revenue that scales with sites/residents. That business model supports predictable cash flows, high customer stickiness from clinical workflows, and margin expansion as deployments scale.
Negative Factors
Large persistent operating cash burn
Sustained negative operating and free cash flow rapidly depletes reserves and forces recurring external financing. Persistent cash burn limits ability to fund sales and product investments organically, raises dilution risk for shareholders, and creates execution risk if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring SaaS model in aged/dementia care
PainChek’s core SaaS licensing to aged‑care and clinical providers creates recurring, contractable revenue that scales with sites/residents. That business model supports predictable cash flows, high customer stickiness from clinical workflows, and margin expansion as deployments scale.
Read all positive factors
PainChek Ltd (PCK) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$30.31M
Dividend YieldN/A
Average Volume (3M)3.56M
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue Growth25.98%
EPS Growth22.10%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PainChek Ltd Business Overview & Revenue Model
Company Description
PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals. The company offers PainChek, which uses camera in smartphones and tablets to capture video that is analyzed in real time...
How the Company Makes Money
PainChek makes money primarily by commercialising access to its PainChek software platform for healthcare and care-provider organisations. Its revenue model is typically software-based (subscription and/or usage-based licensing) where facilities o...
PainChek Ltd Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.59M | 3.36M | 2.67M | 1.95M | 978.57K | 214.80K |
| Gross Profit | 733.87K | 997.74K | 726.66K | 712.51K | -258.82K | -424.21K |
| EBITDA | -6.98M | -7.65M | -9.49M | -8.61M | -6.80M | -7.06M |
| Net Income | -6.96M | -7.67M | -8.31M | -7.57M | -5.72M | -6.06M |
Balance Sheet | ||||||
| Total Assets | 5.54M | 2.15M | 4.18M | 2.80M | 6.65M | 11.81M |
| Cash, Cash Equivalents and Short-Term Investments | 4.78M | 1.62M | 3.56M | 2.51M | 6.14M | 11.42M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.04M | 3.26M | 2.89M | 2.13M | 1.83M | 3.57M |
| Stockholders Equity | 2.49M | -1.11M | 1.29M | 668.13K | 4.82M | 8.24M |
Cash Flow | ||||||
| Free Cash Flow | -6.03M | -6.77M | -7.16M | -6.34M | -7.02M | -4.18M |
| Operating Cash Flow | -6.01M | -6.75M | -7.13M | -6.32M | -7.00M | -4.12M |
| Investing Cash Flow | -17.57K | -12.17K | -34.25K | -12.44K | -21.96K | -60.03K |
| Financing Cash Flow | 9.00M | 4.82M | 8.21M | 2.70M | 1.75M | 9.48M |
PainChek Ltd Technical Analysis
Negative
0.29
Price Trends
0.19
Negative
0.26
Negative
0.36
Negative
Market Momentum
-0.01
Negative
39.22
Neutral
20.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PCK, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.19, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 39.22 is Neutral, neither overbought nor oversold. The STOCH value of 20.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PCK.
PainChek Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$134.30M | 26.51 | 4.37% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$75.20M | -6.28 | -23.86% | ― | 15.99% | 22.05% | |
47 Neutral | AU$18.61M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
44 Neutral | AU$43.60M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$30.31M | -3.13 | -1009.84% | ― | 25.98% | 22.10% |
* Healthcare Sector Average
AU:PCK
PainChek Ltd
0.15
-0.15
-51.51%
AU:M7T
Mach7 Technologies
0.32
<0.01
1.59%
AU:RHT
Resonance Health Ltd
0.04
<0.01
2.63%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.07
-31.82%
AU:ALC
Alcidion Group Limited
0.10
0.02
25.00%
PainChek Ltd Corporate Events
PainChek Options Lapse Simplifies Capital Structure
Mar 27, 2026
PainChek Ltd has announced the expiry of 6,354,951 unexercised options with an exercise price of $0.50, which ceased on 24 March 2026. The lapse of these options, disclosed via an Appendix 3H notification, reduces the pool of potential dilutive se...
PainChek lifts UK aged care sales as global expansion gathers pace
Mar 25, 2026
PainChek has recorded strong sales momentum in the UK aged care market, securing 4,000 new contracted licences that represent 9% quarterly growth and are expected to add about A$230,000 in annual recurring revenue once rolled out. The company says...
PainChek to showcase AI pain assessment platform at virtual healthcare conference
Mar 23, 2026
PainChek Ltd, the ASX-listed developer of AI-driven pain assessment tools for healthcare, has built a globally regulated platform used in thousands of aged care facilities for more than 18 million digital pain assessments. Its smartphone and table...
PainChek Options Expire Unexercised, Simplifying Capital Structure
Mar 3, 2026
PainChek Ltd has announced the cessation of a tranche of listed options, with 16,653,867 PCKAZ options expiring unexercised on 3 March 2026. The lapse of these options slightly simplifies the company’s capital structure but does not raise ne...
PainChek Narrows Grant Support as Loss Widens and Auditor Flags Going Concern
Feb 27, 2026
PainChek Limited reported half-year revenue from continuing operations of $1.73 million for the six months to 31 December 2025, up 5% year on year, but total revenue fell 42% to $1.76 million due to a sharp reduction in grant income. The company&#...
PainChek issues new long-dated employee options to support growth strategy
Feb 11, 2026
PainChek Ltd has issued a total of 325,000 unquoted options under its employee incentive scheme, with exercise prices of $0.04 and $0.0356 and expiries in March and February 2030 respectively. The move underscores the company’s use of long-d...
PainChek Wins US RTM Reimbursement Pathway, Unlocking New Growth in Remote Pain Monitoring
Jan 28, 2026
PainChek has secured an independent US legal opinion confirming its AI-driven PainChek device qualifies as an FDA-regulated medical device for Remote Therapeutic Monitoring reimbursement, enabling US healthcare professionals to use it when submitt...
PainChek schedules investor webinar to follow January quarterly update
Jan 28, 2026
PainChek Ltd, a global medtech company specialising in AI-driven pain assessment tools delivered via smartphones and tablets, has established a strong presence in aged care and related sectors, with regulatory approvals in multiple major markets a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.